EP1237570A4 - Fragments et antagonistes de proteines de choc thermique 60 - Google Patents

Fragments et antagonistes de proteines de choc thermique 60

Info

Publication number
EP1237570A4
EP1237570A4 EP00981586A EP00981586A EP1237570A4 EP 1237570 A4 EP1237570 A4 EP 1237570A4 EP 00981586 A EP00981586 A EP 00981586A EP 00981586 A EP00981586 A EP 00981586A EP 1237570 A4 EP1237570 A4 EP 1237570A4
Authority
EP
European Patent Office
Prior art keywords
antagonists
fragments
heat shock
shock protein
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00981586A
Other languages
German (de)
English (en)
Other versions
EP1237570A2 (fr
Inventor
Hubert Kolb
Dana Elias
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Peptor Ltd
Original Assignee
Peptor Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptor Ltd filed Critical Peptor Ltd
Priority to EP00981586A priority Critical patent/EP1237570A4/fr
Publication of EP1237570A2 publication Critical patent/EP1237570A2/fr
Publication of EP1237570A4 publication Critical patent/EP1237570A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
EP00981586A 1999-12-15 2000-12-14 Fragments et antagonistes de proteines de choc thermique 60 Withdrawn EP1237570A4 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP00981586A EP1237570A4 (fr) 1999-12-15 2000-12-14 Fragments et antagonistes de proteines de choc thermique 60

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US17229799P 1999-12-15 1999-12-15
EP99125035 1999-12-15
US172297P 1999-12-15
EP99125035 1999-12-15
EP00981586A EP1237570A4 (fr) 1999-12-15 2000-12-14 Fragments et antagonistes de proteines de choc thermique 60
PCT/IL2000/000833 WO2001043691A2 (fr) 1999-12-15 2000-12-14 Fragments et antagonistes de proteines de choc thermique 60

Publications (2)

Publication Number Publication Date
EP1237570A2 EP1237570A2 (fr) 2002-09-11
EP1237570A4 true EP1237570A4 (fr) 2005-01-05

Family

ID=32842929

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00981586A Withdrawn EP1237570A4 (fr) 1999-12-15 2000-12-14 Fragments et antagonistes de proteines de choc thermique 60

Country Status (7)

Country Link
EP (1) EP1237570A4 (fr)
JP (1) JP2004501061A (fr)
AU (1) AU784623B2 (fr)
CA (1) CA2394504A1 (fr)
NZ (1) NZ519348A (fr)
WO (1) WO2001043691A2 (fr)
ZA (1) ZA200204635B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL140233A0 (en) * 2000-12-11 2002-02-10 Peptor Ltd Backbone cyclized analogs of heat shock proteins
US7727974B2 (en) 2001-08-10 2010-06-01 Eisai R & D Management Co., Ltd. Methods of reducing the severity of mucositis
US20040254128A1 (en) * 2001-08-10 2004-12-16 Seiichi Kobayashi Treatment and prevention of heat shock protein-associated diseases and conditions
US20030077279A1 (en) * 2001-10-24 2003-04-24 Cedars-Sinai Medical Center Methods for treating vascular disease by inhibiting toll-like receptor-4
EP2157101B1 (fr) 2002-01-31 2014-09-24 Andromeda Bio Tech Ltd. Peptides HSP et analogues pour la modulation de réponses immunes via des cellules présentant l'antigène
WO2003070761A1 (fr) * 2002-02-19 2003-08-28 Yeda Research And Development Co. Ltd. Ligands a double effet comprenant des epitopes de peptides hsp anti-inflammatoires pour l'immunomodulation
WO2005040208A2 (fr) * 2003-10-21 2005-05-06 Androclus Therapeutics, Soa Molecules pour moduler l'activite des recepteurs de type toll et procedes d'utilisation associes
EP1758924B1 (fr) * 2004-06-01 2008-12-31 Council of Scientific and Industrial Research Antagonistes peptidiques permettant d'inhiber la proteine de choc thermique (hsp 16.3) du bacille de koch
CU23504A1 (es) * 2004-09-24 2010-04-13 Ct Ingenieria Genetica Biotech Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas
WO2006072946A2 (fr) 2005-01-04 2006-07-13 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Hsp60, peptides hsp60 et vaccins a base de lymphocytes t pour immunomodulation
JP4283812B2 (ja) * 2006-01-06 2009-06-24 財団法人工業技術研究院 重症筋無力症の診断方法およびそのキット
EP2170361B1 (fr) 2007-07-06 2016-05-25 Universiteit Utrecht Holding B.V. Traitement et prévention de maladies inflammatoires et de maladies auto-immunes
US9512196B2 (en) 2008-09-22 2016-12-06 Cedars-Sinai Medical Center Short-form human MD-2 as a negative regulator of toll-like receptor 4 signaling
EP2328911A4 (fr) 2008-09-22 2012-03-14 Cedars Sinai Medical Center Md-2 humaine sous sa forme courte utilisée comme régulateur négatif de la signalisation par le récepteur de type toll-4
CU23701A1 (es) 2008-12-29 2011-09-21 Ct Ingenieria Genetica Biotech Método de tratamiento de enfermedades inflamatorias intestinales y diabetes tipo i

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998004583A1 (fr) * 1996-07-31 1998-02-05 Peptor Ltd. Analogues de la somatostatine cyclises par squelette a contrainte de conformation
WO1998008536A2 (fr) * 1996-08-30 1998-03-05 Yeda Research And Development Co. Ltd. Methode de reduction de la gravite d'une reaction de l'hote contre le greffon par regulation negative de l'autoimmunite vis-a-vis de hsp60
WO2000020019A2 (fr) * 1998-10-04 2000-04-13 Yehuda Shoenfeld Composition destinee a la prevention et/ou au traitement de l'atherosclerose
WO2002048312A2 (fr) * 2000-12-11 2002-06-20 Peptor Ltd. Inhibiteurs a squelette cyclise de proteines de choc thermique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958416A (en) * 1994-12-16 1999-09-28 Regents Of The University Of Minnesota Heat shock protein peptides and methods for modulating autoimmune central nervous system disease
IL114407A0 (en) * 1995-06-30 1995-10-31 Yeda Res & Dev Novel peptides and pharmaceutical compositions comprising them
US5985270A (en) * 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998004583A1 (fr) * 1996-07-31 1998-02-05 Peptor Ltd. Analogues de la somatostatine cyclises par squelette a contrainte de conformation
WO1998008536A2 (fr) * 1996-08-30 1998-03-05 Yeda Research And Development Co. Ltd. Methode de reduction de la gravite d'une reaction de l'hote contre le greffon par regulation negative de l'autoimmunite vis-a-vis de hsp60
WO2000020019A2 (fr) * 1998-10-04 2000-04-13 Yehuda Shoenfeld Composition destinee a la prevention et/ou au traitement de l'atherosclerose
WO2002048312A2 (fr) * 2000-12-11 2002-06-20 Peptor Ltd. Inhibiteurs a squelette cyclise de proteines de choc thermique

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ABULAFIA-LAPID R ET AL: "T cell proliferative responses of type 1 diabetes patients and healthy individuals to human hsp60 and its peptides", JOURNAL OF AUTOIMMUNITY, LONDON, GB, vol. 12, no. 2, March 1999 (1999-03-01), pages 121 - 129, XP002246459, ISSN: 0896-8411 *
BIRK OHAD S ET AL: "A role of Hsp60 in autoimmune diabetes: Analysis in a transgenic model", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 93, no. 3, 1996, pages 1032 - 1037, XP002291768, ISSN: 0027-8424 *
BOCKOVA J ET AL: "TREATMENT OF NOD DIABETES WITH A NOVEL PEPTIDE OF THE HSP 60 MOLECULE INDUCES TH2-TYPE ANTIBODIES", JOURNAL OF AUTOIMMUNITY, LONDON, GB, vol. 10, no. 4, August 1997 (1997-08-01), pages 323 - 329, XP000881733, ISSN: 0896-8411 *
CHEN W ET AL: "Human 60-kDa heat-shock protein: a danger signal to the innate immune system.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 15 MAR 1999, vol. 162, no. 6, 15 March 1999 (1999-03-15), pages 3212 - 3219, XP002291767, ISSN: 0022-1767 *
KOLB H ET AL: "HEAT SHOCK PROTEINS SIGNAL THROUGH THE LPS RECEPTOR TLR4", JOURNAL OF ENDOTOXIN RESEARCH, CHURCHILL LIVINGSTONE, EDINBURGH, GB, vol. 6, no. 2, 2000, pages 89,ANS49, XP001076880, ISSN: 0968-0519 *
MEDZHITOV R ET AL: "A HUMAN HOMOLOGUE OF THE DROSOPHILA TOLL PROTEIN SIGNALS ACTIVATIONOF ADAPTIVE IMMUNITY", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 388, 24 July 1997 (1997-07-24), pages 394 - 396, XP002056592, ISSN: 0028-0836 *
See also references of WO0143691A3 *
VABULAS R M ET AL: "HEAT SHOCK PROTEINS AS LIGANDS OF TOLL-LIKE RECEPTORS", CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY, SPRINGER, BERLIN,, DE, vol. 270, 2002, pages 169 - 184, XP008017649, ISSN: 0070-217X *

Also Published As

Publication number Publication date
CA2394504A1 (fr) 2001-06-21
EP1237570A2 (fr) 2002-09-11
WO2001043691A3 (fr) 2002-01-10
AU784623B2 (en) 2006-05-18
AU1881601A (en) 2001-06-25
NZ519348A (en) 2006-04-28
ZA200204635B (en) 2004-05-26
WO2001043691A2 (fr) 2001-06-21
JP2004501061A (ja) 2004-01-15

Similar Documents

Publication Publication Date Title
ZA989461B (en) Methods and compositions for the treatment of autoimmune disease using heat shock proteins
IL195649A0 (en) Compositions comprising anti-??v??3 recombinant human antibodies and nucleic acids encoding the same
ZA967758B (en) Therapeutic and prophylactic methods using heat shock proteins
EP1071706A4 (fr) Proteines de fusion gfp a degradation rapide et methodes d'utilisation
EP1242443A4 (fr) Nouveaux acides nucleiques et polypeptides
HUP0200414A2 (en) Interferon-betha fusion proteins and uses
EP0851765A4 (fr) Procedes therapeutique et profilactique utilisant des proteines du choque thermique
EP1007562A4 (fr) PROTEINES TANGO-63d ET TANGO-63e APPARENTEES AU RECEPTEUR DU FACTEUR DE NECROSE DES TUMEURS
PL336213A1 (en) Gnrh antagonists modified at positions 5 and 6
EP1237570A4 (fr) Fragments et antagonistes de proteines de choc thermique 60
EP0988295A4 (fr) Piperidines a substitution heterocyclique et utilisations de ces dernieres
NZ513680A (en) Epitodes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of IgE, antagonists thereof, and their therapeutic uses
IL140239A0 (en) Anti-angiogenic proteins and methods of use thereof
IL140509A0 (en) Expression of functional eukaryotic proteins
HUP0101701A3 (en) Substituted betha-alanines and pharmaceutical compositions comprising them
ZA983065B (en) Inhibitors of protein farnesyltranferase
GB9614033D0 (en) Modified protein G and fragments thereof
GB9930443D0 (en) Novel use of heat shock proteins
AU2002329450A1 (en) Fragements of heat shock proteins and their use
ZA985999B (en) Protein kinases and uses thereof
IL131929A0 (en) Rap protein its preparation and use
AU2001248277A1 (en) Shock heat treatment of polypeptides
IL150113A0 (en) Fragments and antagonists of heat shock protein 60
EP1239039A4 (fr) Nouveau polypeptide et son adn
AU3230500A (en) Isolation and characterization of heat shock protein

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020611

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20041122

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: DEVELOGEN ISRAEL LTD

17Q First examination report despatched

Effective date: 20050929

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20061123